FDA Approves Novel Oral Medication for High Cholesterol

The U.S. Food and Drug Administration has granted approval for Lipfendra (enlicitide), an innovative oral drug designed to lower cholesterol levels in high-risk patients who have not responded adequately to statin therapy. This marks a significant development as it is the first non-injectable medication to target the PCSK9 liver protein, a mechanism previously only accessible through more costly injectable treatments. The new pill offers a convenient alternative for managing elevated cholesterol.